Charles Schwab Investment Management Inc. Has $10.24 Million Stock Holdings in Artivion, Inc. (NYSE:AORT)

Charles Schwab Investment Management Inc. grew its holdings in Artivion, Inc. (NYSE:AORT) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 358,192 shares of the company’s stock after buying an additional 8,343 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.85% of Artivion worth $10,241,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after buying an additional 786 shares in the last quarter. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion in the fourth quarter valued at $43,000. New York State Common Retirement Fund increased its stake in shares of Artivion by 2.5% in the fourth quarter. New York State Common Retirement Fund now owns 41,017 shares of the company’s stock valued at $1,173,000 after buying an additional 1,000 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Artivion in the fourth quarter valued at $78,000. Finally, Principal Financial Group Inc. boosted its holdings in Artivion by 3.8% in the fourth quarter. Principal Financial Group Inc. now owns 202,028 shares of the company’s stock valued at $5,776,000 after acquiring an additional 7,398 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, insider John E. Davis sold 15,100 shares of Artivion stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $23.61, for a total transaction of $356,511.00. Following the transaction, the insider now owns 208,778 shares in the company, valued at $4,929,248.58. The trade was a 6.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 18,020 shares of Artivion stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the transaction, the senior vice president now owns 197,184 shares in the company, valued at $4,655,514.24. This trade represents a 8.37 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,799 shares of company stock worth $2,356,223. Insiders own 8.10% of the company’s stock.

Artivion Price Performance

Shares of AORT opened at $24.47 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 1 year low of $19.36 and a 1 year high of $32.33. The stock has a market cap of $1.03 billion, a P/E ratio of -1,223.50 and a beta of 1.79. The stock’s 50-day moving average price is $28.14 and its two-hundred day moving average price is $27.64.

Artivion (NYSE:AORT) last issued its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. On average, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Needham & Company LLC decreased their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Finally, Stifel Nicolaus decreased their price target on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion currently has an average rating of “Buy” and a consensus target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.